Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Lucas AM, Armbruster B. The cost-effectiveness of expanded HIV screening in the United States. AIDS. 2013 Mar 13;27(5):795-801. doi: 10.1097/QAD.0b013e32835c54f9
Mauskopf JA, Candrilli SD, Chevrou-Severac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol. 2012 Jul 1;10:136.
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS. 2011 Feb 20;25(4):463-71.
Doward LC, Dietz B, Wilburn J, McKenna SP, Bhor M, Rajagopalan R. Impact of lipoatrophy on patient-reported outcomes in ART-experienced patients. AIDS. 2008 May 1;20(10):1197-201.